My watch list  

Cytokine storm

A cytokine storm is a potentially fatal immune reaction consisting of a positive feedback loop between cytokines and immune cells, with highly elevated levels of various cytokines.[1]



The primary symptoms of a cytokine storm are a high fever, swelling and redness, extreme fatigue, and nausea.


When the immune system is fighting pathogens, cytokines signal immune cells such as T-cells and macrophages to travel to the site of infection. In addition, cytokines activate those cells, stimulating them to produce more cytokines. Normally this feedback loop is kept in check by the body. However, in some instances, the reaction becomes uncontrolled, and too many immune cells are activated in a single place. The precise reason for this is not entirely understood, but may be caused by an exaggerated response when the immune system encounters a new and highly pathogenic invader. Cytokine storms have potential to do significant damage to body tissues and organs. If a cytokine storm occurs in the lungs, for example, fluids and immune cells such as macrophages may accumulate and eventually block off the airways, potentially resulting in death.

The cytokine storm (hypercytokinemia) is the systemic expression of a healthy and vigorous immune system resulting in the release of more than 150 inflammatory mediators (cytokines, oxygen free radicals, and coagulation factors). Both pro-inflammatory cytokines (such as Tumor necrosis factor-alpha, Interleukin-1, and Interleukin-6) and anti-inflammatory cytokines (such as interleukin 10, and interleukin 1 receptor antagonist) are elevated in the serum of patients experiencing a cytokine storm.

Cytokine storms can occur in a number of infectious and non-infectious diseases including graft versus host disease (GVHD), adult respiratory distress syndrome (ARDS), sepsis, avian influenza, smallpox, and systemic inflammatory response syndrome (SIRS).[2]

The first reference to the term "cytokine storm" in the published medical literature appears to be by Ferrara et al[3] in GVHD, February 1993.

Role in pandemic deaths

It is believed that cytokine storms were responsible for many of the deaths during the 1918 influenza pandemic, which killed a disproportionate number of young adults (a phenomenon that could repeat itself in future flu pandemics). In this case, a healthy immune system may have been a liability rather than an asset. Preliminary research results from Hong Kong also indicated this as the probable reason of many deaths during the SARS epidemic in 2003. Human deaths from the bird flu H5N1 usually involve cytokine storms as well.

Clinical trials of TGN1412

In March 2006, all 6 men who had received the experimental drug TGN1412 suffered extremely serious symptoms[4][5] from what was likely the effects of a cytokine storm.[6] Based on results from animal trials, the company claimed that TGN1412 could activate T-cells in a way that would not cause the cytokine storm one would expect based on results from other drugs with similar mechanisms of action. All 6 men had been participating in a Phase 1 trial.



A 2003 report in the Journal of Experimental Medicine and published by researchers at Imperial College in London demonstrates[7] the possibility of preventing a cytokine storm by inhibiting or disabling T-cell response. A few days after T cells are activated, they produce a biologic molecule called OX40, a “survival signal” that keeps activated T-cells working at the site of inflammation during infection with influenza or other pathogens. OX40 binds to receptors on T-cells, preventing them from dying and subsequently increasing cytokine production. A combined protein, OX40-immunoglobulin (OX40-Ig), a man-made fusion protein, prevents OX40 from reaching the T-cell receptors, thus reducing the T-cell response. Experiments in mice have demonstrated that OX40-Ig can reduce the symptoms associated with an immune overreaction while allowing the immune system to fight off the virus successfully. By blocking the OX40 receptor on T-cells, researchers were able to prevent the development of the most serious flu symptoms in these experimental mice[7] and reported in New Scientist.[8] The drug, to be made by a company called Xenova Research, was supposed to be in phase I clinical trial in 2004, but its status is currently unknown.[9]

ACE inhibitors and Angiotensin II Receptor Blockers

The Renin Angiotensin system (RAS) has been implicated in the mediation of the cytokine storm,[10] suggesting a potential benefit for Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin II Receptor Blockers (ARBs), and ACE has been implicated in inflammatory lung pathologies.[11] Shigehara et al published research confirming that serum angiotensin-converting enzyme (ACE) is a useful marker for disease activity in cytokine-mediated inflammatory lung disease.[12] Marshall and co-workers also found that angiotensin II was associated with cytokine-mediated lung injury.[13] and suggested a role for ACE inhibitors.

Wang and co-workers published data linking cytokine-mediated pulmonary damage (apoptosis of lung epithelial cells) in response to the pro-inflammatory cytokine TNF-alpha (implicated in the cytokine storm) requires the presence of angiotensin II, suggesting that ARBs might have clinical utility in this setting.[14]

Das published a review of ACE inhibitor and angiotensin-II receptor blocker use in a number of cytokine-mediated inflammatory pathologies and suggested that ACE inhibitors and Angiotensin receptor blockers have theoretical benefit in downregulation of the cytokine storm.[15]


Although frequently employed to treat patients experiencing the cytokine storm associated with ARDS, corticosteroids and NSAIDs have been evaluated in clinical trials and have shown no effect on lung mechanics, gas exchange or beneficial outcome in early established ARDS.[2]

Free Radical Scavengers

Preliminary data from clinical trials involving patients with sepsis-induced ARDS have shown a reduction in organ damage and a trend toward improvement in survival (survival in ARDS is approximately 60%) after administering or upregulating a variety of free radical scavengers (antioxidants) .[2]


  1. ^ Osterholm, Michael T. (2005-05-05). "Preparing for the Next Pandemic". The New England Journal of Medicine 352 (18): 1839-1842. Retrieved on 2007-10-18.
  2. ^ a b c Goldman (ed.); Bennett (ed.) (2000). Cecil Textbook of Medicine, 21st edition. 
  3. ^ Ferrara, JL.; S. Abhyankar, DG. Gilliland (February 1993). "Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1.". Transplant Proc. 2 (25): 1216-1217. PMID 8442093. Retrieved on 2007-10-18.
  4. ^ (February 2007) "Leading Edge: High stakes, high risks". Lancet Oncology 8 (2). The Lancet. doi:10.1016/S1470-2045(07)70004-9. Retrieved on 2007-10-18.
  5. ^ Superagonist Trial Hit By Cytokine Storm -
  6. ^ Mystery over drug trial debacle deepens, New news service, 14 August 2006.
  7. ^ a b Humphreys, IR; G Walzl, L Edwards, A Rae, S Hill, T Hussell (2003-10-20). "A critical role for OX40 in T cell-mediated immunopathology during lung viral infection.". J Exp Med. 198 (8): 1237-1242. PMID 14568982. Retrieved on 2007-10-18.
  8. ^ New flu drug calms the 'storm' - New Scientist
  9. ^ OX-40 Clinical Trial details
  10. ^ Genctoy, G; B Altun et al (February 2005). "TNF alpha-308 genotype and renin-angiotensin system in hemodialysis patients: an effect on inflammatory cytokine levels?". Artif Organs 29 (2): 174-178. PMID 15670287. Retrieved on 2007-10-18.
  11. ^ Moldobaeva, A; EM Wagner (December 2003). "Angiotensin-converting enzyme activity in ovine bronchial vasculature.". J Appl Physiol 95 (6): 2278-2284. Department of Medicine, Johns Hopkins University. PMID 15670287. Retrieved on 2007-10-18.
  12. ^ Shigehara, K; N Shijubo et al (April 2003). "Increased circulating interleukin-12 (IL-12) p40 in pulmonary sarcoidosis.". Clin Exp Immunol 132 (1): 152-157. Sapporo Medical University School of Medicine. PMID 12653850. Retrieved on 2007-10-18.
  13. ^ Marshall, RP; P Gohlke et al (January 2004). "Angiotensin II and the fibroproliferative response to acute lung injury.". Am J Physiol Lung Cell Mol Physiol 286 (1): 156-164. Royal Free and University College London Medical School. PMID 12754187. Retrieved on 2007-10-18.
  14. ^ Wang, R; G Alam et al (November 2000). "Apoptosis of lung epithelial cells in response to TNF-alpha requires angiotensin II generation de novo.". J Cell Physiol 185 (2): 253-259. The Cardiovascular Institute, Michael Reese Hospital and Medical Center. PMID 11025447. Retrieved on 2007-10-18.
  15. ^ Das (May 2005). "Angiotensin-II behaves as an endogenous pro-inflammatory molecule.". J Assoc Physicians India (53): 472-476. UND Life Sciences. PMID 16124358. Retrieved on 2007-10-18.
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Cytokine_storm". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE